Endocannabinoid System in Polycystic Kidney Disease

Jost Klawitter, Cristina Sempio, Matthew J Jackson, Peter H Smith, Katharina Hopp, Michel Chonchol, Berenice Y Gitomer, Uwe Christians, Jelena Klawitter. Am J Nephrol. 2022;53(4):264-272.

Observational studyHumans

Design

Observational study

Subjects

102 patients with autosomal dominant polycystic kidney disease and 100 healthy subjects

Dose used in the study

Not stated in the abstract; no treatment was given

Duration

Baseline and after 2 and 4 years

What was measured

Plasma endocannabinoids and related lipids including palmitoylethanolamide by mass spectrometry; interleukins; kidney volume and eGFR change over time.

What the authors reported

Patients had higher IL-6 and IL-1b and lower plasma AEA, 2-AG and related lipids than healthy people. Baseline AEA was negatively associated with kidney volume growth and positively with change in kidney function, and palmitoylethanolamide was positively associated with yearly change in eGFR.

Limits of this study

An observational cohort that measured natural palmitoylethanolamide; it did not test PEA as a treatment and cannot show cause. Conflict of interest: none stated.

Source

PubMed 35263737 · doi:10.1159/000522113

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.